Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial.

Nataniel Hernan Lester-Coll,Jeffrey G. Supko,Jeannie Kluytenaar,Kira F. Pavlik,James B. Yu,Jennifer Moliterno,Joseph M. Piepmeier,Kevin P. Becker,Joachim M. Baehring,Anita Huttner,Alexander O. Vortmeyer,Joseph N. Contessa,Ramachandran Ramani,Rachel Lampert,Xiaopan Yao,Ranjit S. Bindra

Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial.

2018

Nataniel Hernan Lester-Coll
Jeffrey G. Supko
Jeannie Kluytenaar
Kira F. Pavlik
James B. Yu
Jennifer Moliterno
Joseph M. Piepmeier
Kevin P. Becker
Joachim M. Baehring
Anita Huttner
Alexander O. Vortmeyer
Joseph N. Contessa
Ramachandran Ramani
Rachel Lampert
Xiaopan Yao
Ranjit S. Bindra

e14046Background: Recurrent Glioblastoma Multiforme (GBM) has limited treatment options. We performed a high-throughput screen for DNA repair inhibitors and identified mibefradil dihydrochloride, a...

Keywords:

Glioblastoma
Physical therapy
Radiation
Cancer research
Mibefradil
Medicine
DNA repair
Oncology
Internal medicine
MIBEFRADIL DIHYDROCHLORIDE
Pathology
treatment options
recurrent glioblastoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations